EVIDENCE THAT DOPAMINE IS NOT A SUBSTRATE FOR ADRENAL PHENYLETHANOLAMINE N-METHYLTRANSFERASE = DEMONSTRATION DU FAIT QUE LA DOPAMINE N'EST PAS UN SUBSTRAT DE LA PHENYLETHANOLAMINE-N-METHYLTRANSFERASE DES SURRENALESPENDLETON RG; GESSNER G.1975; MOLEC. PHARMACOL.; U.S.A.; DA. 1975; VOL. 11; NO 2; PP. 232-235; BIBL. 12REF.Article

THE LONG TERM EFFECTS OF AN INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE UPON ADRENAL EPINEPHRINE BIOSYNTHESIS.PENDLETON RG; GESSNER G; JENKINS B et al.1976; ARCH. (NAUNYN-SCHMIEDERBERG'S) PHARMACOL.; GERM.; DA. 1976; VOL. 295; NO 2; PP. 127-133; BIBL. 23 REF.Article

STUDIES ON SK&F7698; AN INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE (PNMT) = RECHERCHES SUR LE SK ET F7698: UN INHIBITEUR DE LA PHENYLETHANOLAMINE N-METHYLTRANSFERASE (PNMT)PENDLETON RG; KAISER C; GESSNER G et al.1974; J. PHARMACOL. EXPER. THERAPEUT.; U.S.A.; DA. 1974; VOL. 190; NO 3; PP. 551-562; BIBL. 35 REF.Article

STUDIES ON SK & F 29661, AN ORGAN-SPECIFIC INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASEPENDLETON RG; GESSNER G; WEINER G et al.1979; J. PHARMARCOL. EXPER. THERAPEUT.; USA; DA. 1979; VOL. 208; NO 1; PP. 24-30; BIBL. 15 REF.Article

STUDIES ON THE CHARACTERIZATION AND INHIBITION OF RAT BRAIN PHENYLETHANOLAMINE N-METHYLTRANSFERASE.PENDLETON RG; JAGJITSINGH KHALSA; GESSNER G et al.1977; ARCH. (NAUNYN-SCHMIEDEBERG'S) PHARMACOL.; GERM.; DA. 1977; VOL. 299; NO 3; PP. 219-224; BIBL. 18 REF.Article

THE EFFECTS OF AN INHIBITOR OF PHENYLETHANOLAMINE N-METHYL-TRANSFERASE UPON STIMULATED ADRENAL CATECHOLAMINE RELEASE AND EXCRETION IN THE RAT.PENDLETON RG; WEINER G; JENKINS B et al.1977; ARCH. (NAUNYN-SCHMIEDEBERG'S) PHARMACOL.; GERM.; DA. 1977; VOL. 297; NO 3; PP. 245-250; BIBL. 12 REF.Article

Studies on inhibition of angiotensin II receptors in rabbit adrenal and aortaPENDLETON, R. G; GESSNER, G; HORNER, E et al.The Journal of pharmacology and experimental therapeutics. 1989, Vol 248, Num 2, pp 637-643, issn 0022-3565Article

Dithiothreitol, sodium chloride, and ethylenediaminetetraacetic acid increase the binding affinity of [¹²⁵I]angiotensin IV to AT₄ receptors in bovine adrenal cortexJARVIS, M. F; GESSNER, G. W.Peptides (New York, NY. 1980). 1994, Vol 15, Num 6, pp 1037-1044, issn 0196-9781Article

Comparative effects of angiotensin II and angiotensin III in rabbit adrenal and aortic tissuesPENDLETON, R. G; GESSNER, G; HORNER, E et al.The Journal of pharmacology and experimental therapeutics. 1991, Vol 256, Num 2, pp 614-620, issn 0022-3565, 7 p.Article

Studies defining minimal receptor domains for angiotensin IIPENDLETON, R. G; GESSNER, G; HORNER, E et al.The Journal of pharmacology and experimental therapeutics. 1989, Vol 250, Num 1, pp 31-36, issn 0022-3565Article

Differential expression of adenosine A_2A and A_2Breceptor subtypes on myeloid U937 and THP-1 cells : Adenosine A_2Breceptor activation selectively stimulates cAMP formation and inhibition of TNFα release in THP-1 cellsMUNRO, R; RESSNER, R; STONE, M et al.Drug development research. 1998, Vol 44, Num 1, pp 41-47, issn 0272-4391Article

Regulation of agonist and antagonist binding to striatal D-1 dopamine receptors: studies using the selective D-1 antagonist [³H]SK&F R-83566FLAIM, K. E; GESSNER, G. W; CROOKE, S. T et al.Life sciences (1973). 1986, Vol 38, Num 23, pp 2087-2096, issn 0024-3205Article

Vasopressin-mediated inhibition of atrial natriuretic factor-stimulated cGMP accumulation in an established smooth muscle cell linePONNAL NAMBI; WHITMAN, M; GESSNER, G et al.Proceedings of the National Academy of Sciences of the United States of America. 1986, Vol 83, Num 22, pp 8492-8495, issn 0027-8424Article

Binding of a novel dopaminergic agonist radioligand [³D]-fenoldopam¹ (SKF 82526) to D-1 receptors in rat striatumFLAIM, K. E; GESSNER, G. W; CROKKE, S. T et al.Life sciences (1973). 1985, Vol 36, Num 15, pp 1427-1436, issn 0024-3205Article

Differential effects of the adenosine A₁ receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranesJARVIS, M. F; GESSNER, G; SHAPIRO, G et al.Brain research. 1999, Vol 840, Num 1-2, pp 75-83, issn 0006-8993Article

Characterization of [¹²⁵I]acidic fibroblast growth factor binding to the cloned human fibroblast growth factor receptor, FGF-flg, on NIH 3T3 cell membranes : inhibitory effects of heparin, pertussis toxin and guanine nucleotidesJARVIS, M. F; GESSNER, G. W; MARTIN, G. E et al.The Journal of pharmacology and experimental therapeutics. 1992, Vol 263, Num 1, pp 253-263, issn 0022-3565Article

Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenesLADD, D. L; WEINSTOCK, J; WISE, M et al.Journal of medicinal chemistry (Print). 1986, Vol 29, Num 10, pp 1904-1912, issn 0022-2623Article

Synthesis, conformation, and dopaminergic activity of 5,6-ethano-bridged derivatives of selective dopaminergic 3-benzazepinesWEINSTOCK, J; HYE-JA OH; DEBROSSE, C. W et al.Journal of medicinal chemistry (Print). 1987, Vol 30, Num 8, pp 1303-1308, issn 0022-2623Article

RG 12915 : a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dogFITZPATRICK, L. R; LAMBERT, R. M; PENDLEY, C. E et al.The Journal of pharmacology and experimental therapeutics. 1990, Vol 254, Num 2, pp 450-455, issn 0022-3565, 6 p.Article

Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylaminesWEINSTOCK, J; GAITANOPOULOS, D. E; STRINGER, O. D et al.Journal of medicinal chemistry (Print). 1987, Vol 30, Num 7, pp 1166-1176, issn 0022-2623Article